Sun Pharmaceuticals, LLC, a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 1983, the company has established itself as a leader in the development and manufacturing of a diverse range of generic and specialty medications. With a strong operational presence across North America, Europe, and Asia, Sun Pharmaceuticals focuses on therapeutic areas such as dermatology, oncology, and cardiology. The company is renowned for its innovative formulations and commitment to quality, offering products that cater to the evolving needs of healthcare providers and patients alike. Notable achievements include a robust portfolio of over 200 generic products and a significant market share in various therapeutic segments. Sun Pharmaceuticals continues to drive advancements in healthcare, solidifying its position as a trusted name in the pharmaceutical landscape.
How does Sun Pharmaceuticals, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Sun Pharmaceuticals, LLC's score of 34 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Sun Pharmaceuticals, LLC, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Edgewell Personal Care Company, which influences its climate commitments and initiatives. As part of its corporate family relationship, Sun Pharmaceuticals inherits climate-related targets and performance metrics from Edgewell Personal Care Company. However, there are no documented reduction targets or specific climate pledges available for Sun Pharmaceuticals at this time. In the context of the industry, it is essential for companies like Sun Pharmaceuticals to engage in meaningful climate action, particularly in light of increasing regulatory pressures and stakeholder expectations regarding sustainability. While specific emissions data and reduction initiatives are not disclosed, the company's alignment with its parent organisation's climate strategies may provide a framework for future commitments.
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 5,902,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 
| Scope 2 | 89,988,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 
| Scope 3 | - | - | - | - | - | - | - | 
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sun Pharmaceuticals, LLC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.